Ceftazidime

Ceftazidime

Clinical data
Pregnancy category	AU: B1 US: B (No risk in non-human studies)
Routes of administration	Intravenous, intramuscular
ATC code	J01DD02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)
Pharmacokinetic data
Bioavailability	91% (IM)
Metabolism	negligible
Elimination half-life	1.6–2 hours
Excretion	90–96% renal
Identifiers
IUPAC name (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)- 2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo- 3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0] oct-2-ene-2-carboxylate
CAS Number	72558-82-8
PubChem CID	91713
DrugBank	APRD00857
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H22N6O7S2
Molar mass	546.58 g/mol

WikiDoc Resources for Ceftazidime
Articles
Most recent articles on Ceftazidime Most cited articles on Ceftazidime Review articles on Ceftazidime Articles on Ceftazidime in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ceftazidime Images of Ceftazidime Photos of Ceftazidime Podcasts & MP3s on Ceftazidime Videos on Ceftazidime
Evidence Based Medicine
Cochrane Collaboration on Ceftazidime Bandolier on Ceftazidime TRIP on Ceftazidime
Clinical Trials
Ongoing Trials on Ceftazidime at Clinical Trials.gov Trial results on Ceftazidime Clinical Trials on Ceftazidime at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ceftazidime NICE Guidance on Ceftazidime NHS PRODIGY Guidance FDA on Ceftazidime CDC on Ceftazidime
Books
Books on Ceftazidime
News
Ceftazidime in the news Be alerted to news on Ceftazidime News trends on Ceftazidime
Commentary
Blogs on Ceftazidime
Definitions
Definitions of Ceftazidime
Patient Resources / Community
Patient resources on Ceftazidime Discussion groups on Ceftazidime Patient Handouts on Ceftazidime Directions to Hospitals Treating Ceftazidime Risk calculators and risk factors for Ceftazidime
Healthcare Provider Resources
Symptoms of Ceftazidime Causes & Risk Factors for Ceftazidime Diagnostic studies for Ceftazidime Treatment of Ceftazidime
Continuing Medical Education (CME)
CME Programs on Ceftazidime
International
Ceftazidime en Espanol Ceftazidime en Francais
Business
Ceftazidime in the Marketplace Patents on Ceftazidime
Experimental / Informatics
List of terms related to Ceftazidime

Overview

Ceftazidime (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negative bacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections. Ceftazidime pentahydrate is marketed under various trade names including Fortum (GSK).

Clinical use

Main article: Cephalosporin

Ceftazidime is usually reserved for the treatment of infections caused by Pseudomonas aeruginosa. It is also used in the empirical therapy of febrile neutropenia, in combination with other antibiotics. The usual dose is 1–2 g IV/IM every 8–12 hours(2 - 3times), though this can vary by the indication, infection severity, and/or renal function of the recipient.

Chemistry

In addition to the syn-configuration of the imino side chain, compared to other third-generation cephalosporins, the more complex moiety (containing two methyl and a carboxylic acid group) confers extra stability to β-lactamase enzymes produced by many Gram-negative bacteria. The extra stability to β-lactamases increases the activity of ceftazidime against otherwise resistant Gram-negative organisms including Pseudomonas aeruginosa. The charged pyridinum moiety increases water-solubility.

See also

• Cephalosporin